Artiva Biotherapeutics $ARTV

Health Care · NASDAQ

$3.78
-0.05 (-1.31%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 29, 2026, the first target we tracked for ARTV.

Artiva Biotherapeutics (ARTV) is trading down at $3.78 (-1.31%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: July 19, 2024 · $12.00 offering · NASDAQ

Analyst price targets on ARTV

One firm's current price target on Artiva Biotherapeutics: $4 — 6% above the current $3.78. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 29, 2026 FirmJefferies RatingHold · maintains Targetat $4.23 · $4 -5% Horizonby Oct 2027 StatusOpen

Entry price $4.23, the close nearest Oct 29, 2026, when the target was reported; the target is -5% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 29, 2027.

Source Jefferies downgrades Artiva Biotherapeutics stock rating to hold Investing.com · Oct 29, 2026 · opens the publisher's site
Jefferies downgraded Artiva Biotherapeutics to Hold from Buy with a price target of $4.00

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Artiva Biotherapeutics revenue & net income history (FY2023–FY2025)

RevenueNet incomeNet margin (right axis, %)
$33.5M−$25.2M−$83.9MFY2023 revenue: $33.5MFY2023 net income: −$28.7M · Net margin −85.8%'23FY2024 revenue: $251.0KFY2024 net income: −$65.4M · Net margin −26045.0%'24FY2025 revenue: $0FY2025 net income: −$83.9M'25−100%−50%0%FY2023 net margin: −85.8%FY2024 net margin: −26045.0% (off the scale, which stops at −100.0%)
Artiva Biotherapeutics annual financial statements
FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$33.5M$251.0K$0
Growth (year over year)—−99.3%−100.0%
Operating income−$30.7M−$67.3M−$89.8M
Operating margin−91.6%−26805.6%—
Net income−$28.7M−$65.4M−$83.9M
Net margin−85.8%−26045.0%—
EPS (diluted)−$35.78−$5.81−$3.43
Balance sheet
Cash and equivalents$53.5M$40.2M$26.7M
Total assets$105.1M$209.6M$130.9M
Total liabilities$50.7M$22.9M$21.0M
Shareholders' equity−$162.0M$186.6M$110.0M
Cash flow
Operating cash flow−$47.4M−$55.0M−$76.8M
Capital expenditure$3.26M$642.0K$2.59M
Free cash flow−$50.7M−$55.7M−$79.3M

From Artiva Biotherapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Artiva Biotherapeutics in the news

Nov 12, 2026 PR Newswire INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTV
Oct 29, 2026 Investing.com Jefferies downgrades Artiva Biotherapeutics stock rating to hold Target

About Artiva Biotherapeutics

Headquarters
San Diego, California From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →